Acute Migraine Therapy: New Drugs and New Approaches
Current Treatment Options in Neurology, 12/27/2010
Monteith TS et al. – Olcegepant (BIBN4096BS) and telcagepant (MK–0974) have been shown to be safe and effective in phase I, II, and (for telcagepant) phase III clinical trials. Other targets under investigation include glutamate (AMPA/kainate), TRPV1, prostanoid EP4, and nitric oxide synthase. With new neural targets and the potential for therapeutic advances, the next era of antimigraine medications is near.